Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Shanghai Henlius Biotech

Clinicaltrial registered13 Nov 2026

Shanghai Henlius Biotech

13 Nov 2026: Trial registered · A Phase I Study of HLX109 in Healthy Participants. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
13 Nov 2026
Title
A Phase I Study of HLX109 in Healthy Participants
Conditions
First in Man Study to Evaluate Initial Safety
Phase
Phase 1
Study Type
Interventional
Status
Not Yet Recruiting
Countries
Australia, China
Country
Australia
Reference
NCT07935941
Location
Australia, China
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Shanghai Henlius Biotech

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Shanghai Henlius Biotech in our registers.

More from Australia

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.